In one deal, Foundation Consumer Healthcare will acquire Teva’s emergency contraception products, including Plan B One-Step and Next Choice One Dose, for $675 million.
Teva will sell its remaining contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million in cash.
Teva will use the money from these deals, along with proceeds from the recent $1.1 billion sale of its intrauterine device, to pay off some loan debt, according to the report.
The deals are expected to close by the end of the year.
More articles on supply chain:
Biosimilars are getting approved, but few have hit the market — here’s why
6 drugmakers in the headlines
FDA approves treatment for common gynecologic infection: 3 things to know
